NASDAQ:ALGS

Aligos Therapeutics Stock News

Healthcare > Biotechnology

Buy ALGS

*Your capital is at risk

$5.14

-0.110 (-2.10%)

At Close: Jun 03, 2026

Aligos Enters into an Exclusive License and Research Collaboration Agreement with Merck to Discover and Develop an Oligonucleotide Therapy for NASH

08:00am, Monday, 07'th Dec 2020

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that it has entered into an Exclusive License and Research Collaboration Agreem

Aligos Therapeutics Announces Presentations at the Jefferies Virtual London Healthcare Conference & the Piper Sandler Annual Healthcare Conference

08:00am, Friday, 13'th Nov 2020

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by